Cancer Research Studies and Clinical Trials

Mercy Health is committed to fighting cancer in all its forms, and part of that fight is investing in medical research and clinical trials to find new ways to battle the disease.

Paducah, KY

Open to Recruiting

• CELC-G-301 (VIKTORIA-1) NCT05501886
  A Phase 3, Open-Label, Randomized, Two-Part Study Comparing Gedatolisib in Combination with Palbociclib and Fulvestrant to Standard-of-Care Therapies in Patients with HR-Positive, HER2-Negative Advanced Breast Cancer Previously Treated with a CDK4/6 Inhibitor in Combination with Non-Steroidal Aromatase Inhibitor Therapy
• GS-US-595-6184 (ASCENT-05):  NCT05633654
  Randomized, open-label, Phase 3 Study of Adjuvant Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician’s Choice in Patients with Triple Negative Breast Cancer Who Have Residual Invasive Disease After surgery and Neoadjuvant Therapy
• CELC-G-302 (VIKTORIA-2) NCT06757634
  A Randomized, Open-Label Phase 3 Study of Fulvestrant and CDK4/6 Inhibitors with or without Gedatolisib as First-Line Treatment in Patients with HR-Positive and HER2-Negative Advanced Breast Cancer
• MK-3475-587:  NCT03486873
  A Multicenter, Open-label, Phase 3 Study to Evaluate the Long-term Safety and Efficacy in Participants who are Currently on Treatment or in Follow-up in Studies That Include Pembrolizumab

Studies to Activate Soon

• TROPION- Lung 10:   NCT06357533
  Phase 3, Randomized, Open-Label Global Study of Datopotamab Deruxtecan(Dato-DXd) in Combination with Rilvegostomig (AZD2936) or Rilvegostomig Monotherapy Versus Pembrolizumab Monotherapy for First-Line Treatment of Patients with Locally-advanced or Metastatic Non-Squamous NSCLC with High PD-L1 Expression (TC >= 50%) and Without Actionable Genomic Alterations
• TEMPUS TIME TRIAL (GEMINI TP-CA-002) NSCLC- NCT05236114: 
  A Longitudinal Multiomic Biomarker Profiling Study of Patients with Non-Small Cell Lung Cancer

Blood Studies Open to Recruiting

• MT2221: 
  Study of Fresh Bone Marrow in patients with Multiple Myeloma Cancer with active disease >5% plasma cells
• MT1410-A: 
  Evaluate Molecular Characteristics in the blood samples of patients with Ovarian or Pancreas-Any Stage Pre-TX/Surgery
• MT2875:  
  Study of Fresh Blood & Urine from Patients with Pancreatic Cancer
• MT3060: 
  Study of Fresh Blood from Cancer patients scheduled to receive Keytruda(pembrolizumab)-NSCLC, HNSCC, TNBC, CRC
• MT0332:
  Study of Frozen Plasma and Buffy Coat from Patients with Stage IV NSCLC Receiving Immunotherapy
• MT1118: 
  Study of Fresh Blood from Patients with Stage III-IV Breast Cancer, Colon Cancer, Prostate Cancer, Non-Small Cell Lung Cancer, or Melanoma. These patients must be treatment naïve (preferred) or can be refractory to treatment at time of collection. If refractory, the patient MUST be enrolled after the cessation of therapy and BEFORE starting another line of therapy. If treatment Naïve, patient must be enrolled before the start of any treatment, or any surgery has been performed.

Studies Active, Not Recruiting

• LOXO-BTK-20019:  NCT04662255
  Phase 3 Open-Label, Randomized Study of LOXO-305 versus Investigator Choice of BTK Inhibitor in Patients with Previously Treated BTK Inhibitor Naïve Mantel Cell lymphoma (BRUIN MCL-321)
• NCI Trial: COSMIC Trial (WF2304) NCT06418204
  Registry Trial for Newly diagnosed with Breast, Colorectal, Melanoma, NHL, NSCLC looking to see how they manage cancer related symptoms